00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
22:14 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Acasti raises $10M in follow-on

Metabolic company Acasti Pharma Inc. (TSX-V:ACST; NASDAQ:ACST) said on Dec. 27, 2017, it raised $10 million in a follow-on underwritten by Benchmark and Dawson James Securities. The offering comprises 9.9 million shares and accompanying warrants...
19:03 , Feb 24, 2017 |  BC Week In Review  |  Financial News

Acasti completes follow-on and private placement of convertible debentures and warrants

Hypertriglyceridemia company Acasti Pharma Inc. (TSX-V:ACST; NASDAQ:ACST) raised C$7.7 million ($5.9 million) in concurrent financings on Feb. 21. In a follow-on underwritten by Echelon Wealth Partners and Leede Jones Gable, Acasti raised C$5.7 million ($4.4...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Omega-3 phospholipids: Bridging study data

An open-label, 4-way crossover bridging study in 56 healthy volunteers showed that a single dose of 4 g oral CaPre met the primary endpoint based on EPA and DHA levels. Specifically, levels of EPA and...
01:18 , May 1, 2015 |  BC Extra  |  Company News

Management tracks

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said President and COO Kare Schultz resigned. Shire plc (LSE:SHP; NASDAQ:SHPG) named Jeff Poulton CFO and director. A Shire employee since 2003, Poulton has been interim CFO since December. Cardiovascular...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

Omega-3 phospholipids: Phase II data

Top-line data from the double-blind, Canadian Phase II TRIFECTA trial in 365 evaluable patients with mild to severe hypertriglyceridemia showed that once-daily 1 and 2 g CaPre each met the primary endpoint of reducing mean...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Acasti Pharma Inc management update

Acasti Pharma Inc. (TSX-V:APO; NASDAQ:ACST), Laval, Quebec   Business: Cardiovascular   Resigned: Xavier Harland as CFO; his duties will be assumed by interim President and CEO Andre Godin   ...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Neptune Technologies management update

Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT; TSX:NTB), Laval, Quebec   Business: Nutraceuticals, Cardiovascular, Neurology   Transitioned: Andre Godin, CFO of Neptune, to interim president and CEO of Neptune and Neptune's Acasti Pharma Inc. and NeuroBioPharm subsidiaries;...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Neptune Technologies & Bioressources Inc management update

Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT; TSX:NTB), Laval, Quebec   Business: Nutraceuticals, Cardiovascular, Neurology   Resigned: Henri Harland as president and CEO of Neptune and Neptune's NeuroBioPharm Inc. and Acasti Pharma Inc. subsidiaries, while remaining a...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Acasti, Enzymotec, Neptune Technologies nutraceuticals news

The companies reached a settlement agreement related to Neptune's patents for marine omega-3 phospholipids, ending an International Trade Commission (ITC) investigation and ongoing suit in U.S. court. Enzymotec received a non-exclusive, worldwide license to...